2-胍基-4-噻唑羧酸乙酯 | 82982-26-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 中文名称: 2-胍基-4-噻唑羧酸乙酯
• 英文名称: 2-guanidinothiazole-4-carboxylic acid ethyl ester
• 英文别名: 2-guanidino-4-thiazole carboxylic acid ethyl ester；2-guanidino-4-ethoxycarbonylthiazole；(4-Ethoxycarbonylthiazol-2-yl)guanidine；ethyl 2-(diaminomethylideneamino)-1,3-thiazole-4-carboxylate
• CAS: 82982-26-1
• 化学式: C₇H₁₀N₄O₂S
• mdl: MFCD01313282
• 分子量: 214.248
• InChiKey: LBSBQVAGEVSBQP-UHFFFAOYSA-N

物化性质

• 熔点：
  220-222
• 密度：
  1.56±0.1 g/cm3 (20 ºC 760 Torr)

计算性质

• 辛醇/水分配系数(LogP)：
  0.3
• 重原子数：
  14
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.285
• 拓扑面积：
  132
• 氢给体数：
  2
• 氢受体数：
  5

安全信息

• 危险品标志：
  Xi

反应信息

• 作为反应物：
  描述：

  2-胍基-4-噻唑羧酸乙酯 在 一水合肼 作用下， 以 乙醇 为溶剂， 反应 3.5h， 以82%的产率得到2-guanidino-4-thiazolohydrazide
  参考文献：
  名称：

  Bioisosteric prototype design of biaryl imidazolyl and triazolyl competitive histamine H2-receptor antagonists

  摘要：

  The structural relationship of the competitive histamine H2-receptor antagonist 3-amino-5-(2-amino-4-pyridyl)-1,2,4-triazole (1) to the agonist histamine and to antagonists of the cimetidine type was explored by the design and synthesis of four series of bioisosterically designed prototypes. Biological data from these series was best interpreted as indicating a similarity between the imidazole moiety of histamine and cimetidine and the 2-amino-4-pyridyl moiety of 1. On the basis of this data, sequential replacement of 2-amino-4-pyridyl by 2-[(dimethylamino)methyl]-5-furyl and 2-guanidino-4-triazolyl moieties led to a structurally more potent series of biaryl histamine H2-receptor antagonists. The best of these, 2-methyl-4-(2-guanidino-4-thiazolyl)imidazole (29, CP-57,361-1) was 120 times more potent as a histamine H2-receptor antagonist than 1.

  DOI：

  10.1021/jm00161a005
• 作为产物：
  描述：

  脒基硫脲 、 3-溴丙酮酸乙酯 在 水 、 乙酸乙酯 作用下， 以 乙醇 为溶剂， 反应 2.5h， 以to give 2-guanidino-4-ethoxycarbonylthiazole (3.6 g) as crystals的产率得到2-胍基-4-噻唑羧酸乙酯
  参考文献：
  名称：

  2-Guanidino-4-hydroxymethylthiazole and derivatives thereof

  摘要：

  一种化合物的式子：##STR1## 其中R为氢，C.sub.1 -C.sub.5 酰基或取代磺酰基，可用作2-胍基-4-[2-(甲酰胺)乙硫甲基]噻唑，组胺H.sub.2受体拮抗剂的合成中间体。

  公开号：

  US04492794A1

文献信息

• Thiazole derivatives
  申请人：Hoffman-La Roche Inc.

  公开号：US06100282A1

  公开（公告）日：2000-08-08

  Compounds of the formula: as well as pharmaceutically usable salts and esters thereof, wherein R.sup.1, R.sup.2 and R.sup.3 have the significance ascribed herein, inhibit binding of adhesive proteins to the surface of different types of cell and accordingly influence cell--cell and cell-matrix interactions. These compounds can be used in the form of pharmaceutical preparations for the control or prevention of neoplasms, tumor metastasing, tumor growth, osteoporosis, Paget's disease, diabetic retinopathy, macular degeneration, restenosis following vascular intervention, psoriasis, arthritis, fibrosis, kidney failure, as well as infection caused by viruses, bacteria or fungi.

  该公式化合物及其药用盐和酯，其中R.sup.1、R.sup.2和R.sup.3具有本文所述的意义，抑制粘附蛋白质与不同类型细胞表面的结合，从而影响细胞间和细胞-基质相互作用。这些化合物可用作药物制剂，用于控制或预防肿瘤、肿瘤转移、肿瘤生长、骨质疏松症、帕金森病、糖尿病视网膜病变、黄斑变性、血管介入后再狭窄、牛皮癣、关节炎、纤维化、肾功能衰竭，以及由病毒、细菌或真菌引起的感染。
• [EN] BIFLUORODIOXALANE-AMINO-BENZIMIDAZOLE KINASE INHIBITORS FOR THE TREATMENT OF CANCER, AUTOIMMUNEINFLAMMATION AND CNS DISORDERS<br/>[FR] INHIBITEURS DE KINASE DIFLUORODIOXALANE-AMINOBENZIMIDAZOLE POUR LE TRAITEMENT D'UN CANCER, D'UNE INFLAMMATION AUTO-IMMUNE ET DE TROUBLES DU SNC
  申请人：4SC DISCOVERY GMBH

  公开号：WO2014001464A1

  公开（公告）日：2014-01-03

  The invention relates to a compound of the general formula (I) or a physiologically functional derivative, solvate or salt thereof, (I) wherein A is a bond, alkyl or alkoxy optionally substituted with one or more R" as defined herein, *-N(R"')CO-, *-CON(R"')-, *-N(R'")CON(R"')-, -S-, -SO-, *-N(R'")-, *-N(R'")CO-, *-CON(R'")-, -CO-, *-COO-, *-OOC-, *-S02N(R"')-, -S02, or *-N(R"')-SO2-, wherein R"' is as defined herein and * specifies the point of attachment to X; X is aryl, cycloalkyl, aralkyl, heterocyclyl or heteroaryl, which may be substituted with one or more Rx further described herein; L is a bond or *-N(RN)CO-, *-CON(RN)-, *-N(RN)-, *-C=N(RN)-, *-N(RN)-alkyI-, *-alkyl-N(RN)-, *-N(RN)CON(RN)-, *-CO-, *-S02-, alkyl, *-alkyl-0-alkyl-, *-NCO-CH=CH-, *-CH=CH-CONH-, * -S02N(RN)-, *-N(RN)S02-, or heterocyclyl, wherein * specifies the point of attachment to X; Y is H, alkyl, aryl, aralkyl, cycloalkyl, heterocyclyl or heteroaryl, which may be substituted with one or more RY further described herein; and R and RN are further described herein; as well as their use as a medicament, a pharmaceutical composition comprising them, a method of treatment or prevention of a medical condition entailing the administration thereof, and the use thereof in the manufacture of a medicament for the treatment or prevention of a medical condition, particularly autoimmune inflammatory disorders, CNS disorders, sleeping disorders, or proliferative diseases including cancer. The invention further relates to a specific process for the preparation of said compounds.

  该发明涉及一般式(I)的化合物或其生理功能衍生物、溶剂或盐，其中(I)中A是键，烷基或烷氧基，可选择地用一个或多个如下所定义的R"取代，*-N(R"')CO-，*-CON(R"')-，*-N(R'")CON(R"')-，-S-，-SO-，*-N(R'")-，*-N(R'")CO-，*-CON(R'")-，-CO-，*-COO-，*-OOC-，*-S02N(R"')-，-S02，或*-N(R"')-SO2-，其中R"'如此定义，*指定连接到X的点；X是芳香族，环烷基，芳基烷基，杂环烷基或杂芳基，可用一个或多个Rx进一步描述；L是键或*-N(RN)CO-，*-CON(RN)-，*-N(RN)-，*-C=N(RN)-，*-N(RN)-烷基-，*-烷基-N(RN)-，*-N(RN)CON(RN)-，*-CO-，*-S02-，烷基，*-烷基-0-烷基-，*-NCO-CH=CH-，*-CH=CH-CONH-，*-S02N(RN)-，*-N(RN)S02-，或杂环烷基，其中*指定连接到X的点；Y是H，烷基，芳基，芳基烷基，环烷基，杂环烷基或杂芳基，可用一个或多个RY进一步描述；R和RN在此进一步描述；以及它们作为药物的用途，包括它们的药物组合物，治疗或预防涉及其管理的医疗状况的方法，以及在制造用于治疗或预防医疗状况的药物中的用途，特别是自身免疫性炎症性疾病、中枢神经系统疾病、睡眠障碍或包括癌症在内的增殖性疾病。该发明还涉及一种特定的制备上述化合物的过程。
• 2-Guanidino-4-heteroarylthiazoles
  申请人：Pfizer Inc.

  公开号：US04374843A1

  公开（公告）日：1983-02-22

  A series of 2-guanidino-4-heteroarylthiazoles, wherein the heteroaryl substituent is selected from thiazolyl, triazolyl, imidazolyl, and 2-alkyl, 2-amino and 2-carboxamido derivatives thereof, are disclosed. The novel compounds have activity as antisecretory agents and histamine H.sub.2 antagonists and are useful for the treatment of gastric hyperacidity and peptic ulcers. Also disclosed are pharmaceutical compositions containing the novel compounds of this invention and a method of using the compounds in the treatment of gastric hyperacidity and peptic ulcers. Novel intermediates useful in the preparation of the novel antisecretory compounds are also described.

  本发明揭示了一系列2-胍基-4-杂环芳基噻唑，其中杂环芳基取代基选自噻唑基、三唑基、咪唑基以及其2-烷基、2-氨基和2-羧酰胺衍生物。这些新颖的化合物具有抗分泌作用和组胺H.sub.2拮抗剂活性，可用于治疗胃酸过多和消化性溃疡。还揭示了含有本发明新化合物的药物组合物以及使用这些化合物治疗胃酸过多和消化性溃疡的方法。还描述了在制备新型抗分泌化合物中有用的新颖中间体。
• 2-Guanidino-4-hydroxymethylthiazole and derivatives thereof
  申请人：Shionogi & Co., Ltd.

  公开号：US04492794A1

  公开（公告）日：1985-01-08

  A compound of the formula: ##STR1## wherein R is hydrogen, C.sub.1 -C.sub.5 alkanoyl or substituted sulfonyl, which is useful as a synthetic intermediate to 2-guanidino-4-[2-(formamido)ethylthiomethyl]thiazole, histamine H.sub.2 receptor antagonist.

  一种化合物的分子式: ##STR1## 其中R为氢、C.sub.1-C.sub.5烷酰基或取代磺酰基，该化合物可用作合成2-胍基-4-[2-(甲酰胺)乙硫甲基]噻唑，组胺H.sub.2受体拮抗剂的中间体。
• BIFLUORODIOXALANE-AMINO-BENZIMIDAZOLE KINASE INHIBITORS FOR THE TREATMENT OF CANCER, AUTOIMMUNEINFLAMMATION AND CNS DISORDERS
  申请人：4SC DISCOVERY GMBH

  公开号：US20150158878A1

  公开（公告）日：2015-06-11

  The invention relates to a compound of the general formula (I) or a physiologically functional derivative, solvate or salt thereof, wherein A, X, L, Y, R, and R N are as defined herein. The invention further relates to the use of the compounds of formula (I) as a medicament, a pharmaceutical composition comprising them, a method of treatment or prevention of a medical condition entailing the administration thereof, and the use thereof in the manufacture of a medicament for the treatment or prevention of a medical condition, particularly autoimmune inflammatory disorders, CNS disorders, sleeping disorders, or proliferative diseases including cancer. The invention further relates to a specific process for the preparation of said compounds.

  本发明涉及一种通式(I)的化合物或其生理功能衍生物、溶剂或盐，其中A、X、L、Y、R和RN如本文所定义。本发明还涉及将通式(I)的化合物用作药物，包括它们的制药组合物，以及治疗或预防需要其给药的医疗状况的方法，以及将其用于制造治疗或预防医疗状况的药物，尤其是自身免疫炎症性疾病、中枢神经系统疾病、睡眠障碍或增殖性疾病，包括癌症。本发明还涉及一种特定的制备上述化合物的方法。